Aberdeen Group Boosts Stake in ARS Pharmaceuticals

Institutional investor increases ownership in biotech firm by nearly 15%

Apr. 5, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Aberdeen Group plc, a major institutional investor, has increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 14.8% during the fourth quarter of 2025. The firm now owns approximately 3.56 million shares, or 3.6% of the biopharmaceutical company focused on developing treatments for severe allergic reactions.

Why it matters

This significant increase in ownership by a prominent institutional investor signals confidence in ARS Pharmaceuticals' growth potential and the prospects of its lead drug candidate, neffy, a needle-free intranasal epinephrine spray for emergency allergy treatment. The stock purchase also highlights the broader investor interest in the specialty pharmaceutical sector.

The details

According to a regulatory filing, Aberdeen Group acquired an additional 459,027 shares of ARS Pharmaceuticals during the fourth quarter, bringing its total position to 3,556,049 shares. This makes Aberdeen one of the largest institutional shareholders of the company. ARS Pharmaceuticals is developing neffy, a novel intranasal epinephrine product that could provide a more convenient and accessible option for treating anaphylaxis, a severe and potentially life-threatening allergic reaction.

  • Aberdeen Group disclosed the increased stake in a filing with the Securities and Exchange Commission on April 5, 2026.
  • The share purchase occurred during the fourth quarter of 2025.

The players

Aberdeen Group plc

A major global investment management firm that has increased its stake in ARS Pharmaceuticals to become one of the company's largest institutional shareholders.

ARS Pharmaceuticals, Inc.

A biopharmaceutical company developing treatments for severe allergic reactions, including its lead drug candidate neffy, a needle-free intranasal epinephrine spray.

Got photos? Submit your photos here. ›

What they’re saying

“Aberdeen Group's increased investment in ARS Pharmaceuticals reflects our confidence in the company's growth potential and the promise of its innovative allergy treatment pipeline.”

— Aberdeen Group spokesperson

What’s next

ARS Pharmaceuticals is expected to provide an update on the development progress of neffy and its other pipeline programs in its upcoming quarterly earnings report.

The takeaway

The sizable investment by Aberdeen Group underscores the institutional investor interest in specialty pharmaceutical companies like ARS that are developing novel solutions for unmet medical needs. This transaction highlights the potential of ARS Pharmaceuticals' intranasal epinephrine technology to disrupt the emergency allergy treatment market.